SCHEMBL4019869

SCHEMBL4019869

N#Cc1ccccc1C(=O)Nc1[nH]nc2c1CN(C(N)=O)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 2/20 0.41
CDK2 P24941 2/20 0.41
CCNA1 P78396 2/20 0.41
OPRK1 P41145 1/20 0.38
AURKA O14965 2/20 0.36
AURKB Q96GD4 1/20 0.36
PPIA P62937 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
EPHB3 P54753 1/20 0.35
TLK2 Q86UE8 1/20 0.34
LRRK2 Q5S007 2/20 0.33
CHRM3 P20309 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020701 0.89 CCNA2 (0.44) CCNA2CDK2CCNA1OPRK1AURKA
SCHEMBL4017921 0.85 OPRK1 (0.38) CCNA2CDK2CCNA1OPRK1AURKA
SCHEMBL2923770 0.85 KDM4E (0.41) CCNA2CDK2CCNA1LMNAPOLB
SCHEMBL2922702 0.84 NPC1 (0.47) CCNA2CDK2CCNA1LMNAMEN1
SCHEMBL2914413 0.84 CCNA2 (0.40) CCNA2CDK2CCNA1AURKAHDAC3
SCHEMBL2916145 0.84 CCNA2 (0.43) CCNA2CDK2CCNA1POLBMAPT
SCHEMBL2917812 0.84 ALPL (0.43) CCNA2CDK2CCNA1POLBMAPT
SCHEMBL2920561 0.83 TMPRSS2 (0.43) CCNA2CDK2CCNA1LMNAPOLB
SCHEMBL4027187 0.83 CCNA2 (0.39) CCNA2CDK2CCNA1AURKALMNA
SCHEMBL2921371 0.82 ADORA3 (0.45) LMNAMEN1MAPTKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531531-B2 Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles PFIZER ITALIA S.R.L. (IT) 2009-05-12 US disclosed
US-20070191386-A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191386-A1 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K19, MAP3K1 CCNA2 848/4885CDK2 43/4885CCNA1 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.